A share price of INmune Bio Inc [INMB] is currently trading at $10.16, up 10.20%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The INMB shares have gain 20.09% over the last week, with a monthly amount glided 118.49%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
INmune Bio Inc [NASDAQ: INMB] stock has seen the most recent analyst activity on January 28, 2025, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $23. Previously, Alliance Global Partners started tracking the stock with Buy rating on October 21, 2024, and set its price target to $20. On September 27, 2024, Raymond James initiated with a Outperform rating and assigned a price target of $18 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $22 on August 22, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $16 as its price target on June 01, 2023. B. Riley Securities downgraded its rating to Neutral for this stock on May 24, 2022, and downed its price target to $7. In a note dated July 07, 2021, Maxim Group reiterated an Buy rating on this stock and boosted its target price from $32 to $42.
INmune Bio Inc experienced fluctuations in its stock price throughout the past year between $4.32 and $14.74. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. INmune Bio Inc [NASDAQ: INMB] shares were valued at $10.16 at the most recent close of the market. An investor can expect a potential return of 116.54% based on the average INMB price forecast.
Analyzing the INMB fundamentals
Trailing Twelve Months sales for INmune Bio Inc [NASDAQ:INMB] were 0.04M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -989.21%, Pretax Profit Margin comes in at -982.67%, and Net Profit Margin reading is -982.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.78, Equity is -1.16 and Total Capital is -1.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.33 points at the first support level, and at 8.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.66, and for the 2nd resistance point, it is at 11.17.
Ratios To Look Out For
To put it in perspective, the Current Ratio for INmune Bio Inc [NASDAQ:INMB] is 2.59. Further, the Quick Ratio stands at 2.59, while the Cash Ratio is 2.43. Considering the valuation of this stock, the price to sales ratio is 5631.75, the price to book ratio is 5.82.
Transactions by insiders
Recent insider trading involved Moss David J, Chief Financial Officer, that happened on Sep 30 ’24 when 10000.0 shares were purchased. President and CEO, Tesi Raymond Joseph completed a deal on Sep 12 ’24 to buy 15380.0 shares. Meanwhile, Chief Financial Officer Moss David J bought 7690.0 shares on Sep 12 ’24.
